Your browser doesn't support javascript.
loading
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
Scott, James S; Moss, Thomas A; Balazs, Amber; Barlaam, Bernard; Breed, Jason; Carbajo, Rodrigo J; Chiarparin, Elisabetta; Davey, Paul R J; Delpuech, Oona; Fawell, Stephen; Fisher, David I; Gagrica, Sladjana; Gangl, Eric T; Grebe, Tyler; Greenwood, Ryan D; Hande, Sudhir; Hatoum-Mokdad, Holia; Herlihy, Kara; Hughes, Samantha; Hunt, Thomas A; Huynh, Hoan; Janbon, Sophie L M; Johnson, Tony; Kavanagh, Stefan; Klinowska, Teresa; Lawson, Mandy; Lister, Andrew S; Marden, Stacey; McGinnity, Dermot F; Morrow, Christopher J; Nissink, J Willem M; O'Donovan, Daniel H; Peng, Bo; Polanski, Radoslaw; Stead, Darren S; Stokes, Stephen; Thakur, Kumar; Throner, Scott R; Tucker, Michael J; Varnes, Jeffrey; Wang, Haixia; Wilson, David M; Wu, Dedong; Wu, Ye; Yang, Bin; Yang, Wenzhan.
Afiliação
  • Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Moss TA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Balazs A; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Breed J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Carbajo RJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Chiarparin E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Davey PRJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Delpuech O; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Fawell S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Fisher DI; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Gagrica S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Gangl ET; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Grebe T; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Greenwood RD; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hande S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Hatoum-Mokdad H; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Herlihy K; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hughes S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hunt TA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Huynh H; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Janbon SLM; Early Chemical Development, Pharmaceutical Sciences, R&D, Macclesfield, United Kingdom.
  • Johnson T; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Kavanagh S; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Klinowska T; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Lawson M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Lister AS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Marden S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States.
  • McGinnity DF; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Morrow CJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Nissink JWM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • O'Donovan DH; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Peng B; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Polanski R; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Stead DS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Stokes S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Thakur K; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Throner SR; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Tucker MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Varnes J; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Wang H; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Wilson DM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States.
  • Wu Y; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Yang B; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Yang W; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States.
J Med Chem ; 63(23): 14530-14559, 2020 12 10.
Article em En | MEDLINE | ID: mdl-32910656
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Moduladores Seletivos de Receptor Estrogênico / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Moduladores Seletivos de Receptor Estrogênico / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article